TQG 202
Alternative Names: Factor VIII biosimilar - Alphamab; KN 008Latest Information Update: 12 Feb 2026
At a glance
- Originator Alphamab
- Developer Chia Tai Tianqing Pharmaceutical Group
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Factor VIII replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Haemophilia A
Most Recent Events
- 12 Feb 2026 TQG 202 is still in phase III trial for Haemophilia A (Treatment-experienced) in China (IV) (NCT04061109)
- 07 Mar 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase III trial in Hemophilia A (Treatment-experienced) in China (Parenteral) in April 2024 (NCT06297655)
- 06 Nov 2022 Adverse events and pharmacokinetics data from a phase III in haemophilia A released by Chia Tai Tianqing Pharmaceutical